Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update

Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals: 2014 Update Author(s): Michael Klompas, MD, MPH; Richard Branson, MSc, RRT; Eric C. Eichenwald, MD; Linda R. Greene, RN, MPS, CIC; Michael D. Howell, MD, MPH; Grace Lee, MD; Shelley S. Magill, MD, PhD; Lisa L. Maragakis, MD, MPH; Gregory P. Priebe, MD; Kathleen Speck, MPH; Deborah S. Yokoe, MD, MPH; Sean M. Berenholtz, MD, MHS Source: Infection Control and Hospital Epidemiology, Vol. 35, No. 8 (August 2014), pp. 915-936 Stable URL: .
Accessed: 21/07/2014 17:07 Your use of the JSTOR archive indicates your acceptance of the Terms & Conditions of Use, available at .
JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range ofcontent in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new formsof scholarship. For more information about JSTOR, please contact [email protected].
The University of Chicago Press and The Society for Healthcare Epidemiology of America are collaboratingwith JSTOR to digitize, preserve and extend access to Infection Control and Hospital Epidemiology. This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 Strategies to Prevent Ventilator-Associated Pneumonia
in Acute Care Hospitals: 2014 Update
Michael Klompas, MD, MPH;1,2 Richard Branson, MSc, RRT;3 Eric C. Eichenwald, MD;4
Linda R. Greene, RN, MPS, CIC;5 Michael D. Howell, MD, MPH;6 Grace Lee, MD;1,7
Shelley S. Magill, MD, PhD;8 Lisa L. Maragakis, MD, MPH;9 Gregory P. Priebe, MD;2,7,10
Kathleen Speck, MPH;11 Deborah S. Yokoe, MD, MPH;2 Sean M. Berenholtz, MD, MHS11,12,13
surveillance definitions are subjective and nonspecific.
Historically, 10%–20% of ventilated patients have de- Previously published guidelines are available that provide veloped VAP. More recent reports suggest much lower comprehensive recommendations for detecting and prevent- rates, but it is unclear to what extent these lower rates ing healthcare-associated infections (HAIs). The intent of this reflect better care versus stricter application of subjec- document is to highlight practical recommendations in a con- tive surveillance criteria.3,4 Notwithstanding surveil- cise format to assist acute care hospitals in implementing and lance rates that hover near zero, clinical surveys suggest prioritizing strategies to prevent ventilator-associated pneu- that 5%–15% of ventilated patients still develop nos- monia (VAP) and other ventilator-associated events (VAEs) ocomial pneumonias.5-9 and to improve outcomes for mechanically ventilated adults, B. Patients on mechanical ventilation are at risk for a va- children, and neonates. This document updates "Strategies riety of serious complications in addition to pneumo- to Prevent Ventilator-Associated Pneumonia in Acute Care nia. These include acute respiratory distress syndrome, Hospitals," published in 2008.1 This expert guidance docu- pneumothorax, pulmonary embolism, lobar atelectasis, ment is sponsored by the Society for Healthcare Epidemiology and pulmonary edema. The Centers for Disease Control of America (SHEA) and is the product of a collaborative effort and Prevention (CDC) released new surveillance defi- led by SHEA, the Infectious Diseases Society of America nitions for VAE designed to make surveillance more (IDSA), the American Hospital Association (AHA), the As- objective and to expand surveillance from VAP alone sociation for Professionals in Infection Control and Epide- to include additional serious complications of mechan- miology (APIC), and The Joint Commission, with major con- ical ventilation (see section 2). VAE definitions include tributions from representatives of a number of organizations criteria for ventilator-associated conditions (VACs), and societies with content expertise. The list of endorsing and supporting organizations is presented in the introduction to (IVACs), possible pneumonia, and probable pneumo- the 2014 updates.2 nia. Approximately 5%–10% of mechanically ventilated patients develop VAEs.10-16 II. VAP and other complications of mechanical ventilation are detrimental to patients and increase costs I. Patients on mechanical ventilation are at high risk for VAP A. The attributable mortality of VAP is estimated to be and other complications approximately 10% but varies considerably for different A. The true incidence of VAP is difficult to determine since kinds of patients.17-20 Affiliations: 1. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts; 2. De- partment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; 3. Department of Surgery, University of Cincinnati, Ohio; 4. Division ofNeonatal-Perinatal Medicine, University of Texas Medical School at Houston, Houston, Texas; 5. Highland Hospital, University of Rochester Medical CenterAffiliate, Rochester, New York; 6. Department of Medicine, University of Chicago, Chicago, Illinois; 7. Department of Medicine, Boston Children's Hospital,Boston, Massachusetts; 8. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia; 9. Department ofMedicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; 10. Department of Anesthesiology, Perioperative and Pain Medicine, BostonChildren's Hospital, Boston, Massachusetts; 11. Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine,Baltimore, Maryland; 12. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; 13. Department of Health Policyand Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Received April 14, 2014; accepted April 16, 2014; electronically published July 16, 2014.
Infect Control Hosp Epidemiol 2014;35(8):915-936䉷 2014 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2014/3508-0001$15.00. DOI: 10.1086/677144 This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 B. Both VAP and VAC extend patients' duration of me- unit (ICU) and the hospital, and increased hospital chanical ventilation, increase intensive care and hospital mortality.10-13 Early data suggest that VACs may be length of stay, and increase mortality risk.11,14-16,20,21 preventable.14,42 Surveillance using these definitions They are also associated with increased use of anti- is efficient and potentially automatable.10,11,15 b. The VAE surveillance framework includes 3 defi- C. VAP increases direct medical costs.21 Excess costs at- nition tiers. These definitions are briefly summa- tributable to VAC have not been quantified.
rized below, but readers are advised to consult theCDC's surveillance protocol for comprehensive (a) VAC is defined by greater than or equal to 2 I. Despite VAP's clinical importance, our ability to conduct days of stable or decreasing daily minimum accurate VAP surveillance is very limited.
positive end expiratory pressure (PEEP) or A. VAP is usually defined by clinical, radiographic, and mi- daily minimum fraction of inspired oxygen crobiological criteria. These signs are neither sensitive (Fio ) followed by an increase in daily min- nor specific relative to histopathology.22-25 These criteria imum PEEP greater than or equal to 3 cm of are also very subjective, leading to substantial interob- H O or daily minimum Fio greater than or server variability.8,9,26-29 Administrative data are similarly equal to 0.20 points sustained for greater than inaccurate.7,30-32 Improvements in VAP rates do not re- or equal to 2 calendar days.
liably correlate with improvements in outcomes.33,34 1. The weaknesses of traditional VAP surveillance def- (a) IVAC is triggered by the presence of possible initions limit their utility for measuring the impact infection indicators concurrent with VAC of care improvement programs and for benchmark- onset, namely, an abnormal temperature (be- ing quality of care between different healthcare fa- low 36⬚C or above 38⬚C) or white blood cell count (less than or equal to 4,000 or greater II. CDC's VAE framework than or equal to 12,000 cells/mm3) and 1 or A. The CDC convened representatives from critical and more new antibiotic starts that continue for respiratory care, infectious diseases, healthcare epide- greater than or equal to 4 days.
miology, and infection prevention professional societies iii. Possible VAP and probable VAP in 2011–2012 to develop a new approach to surveillance (a) Possible VAP is defined as Gram stain evi- for mechanically ventilated patients in an attempt to dence of purulent pulmonary secretions or overcome some of the limitations of traditional VAP a pathogenic pulmonary culture in a patient with IVAC. Probable VAP is defined as Gram 1. The working group recommended the following: stain evidence of purulence plus quantitative a. Developing new definitions based on objective, quantitative criteria to increase the reliability, re- or semiquantitative growth of a pathogenic producibility, comparability, and efficiency of organism beyond specified thresholds. Prob- able VAP can also be triggered by positive b. Broadening the focus of surveillance from pneu- tests for respiratory viruses, Legionella spe- monia alone to complications of mechanical ven- cies, pleural fluid cultures, and suggestive tilation in general. This simultaneously sidesteps histopathology with or without an abnormal VAP definitions' poor specificity and emphasizes Gram stain result.
the importance of preventing all complications of iv. VAC and IVAC were developed to be appro- mechanical ventilation, not just pneumonia.
priate for public reporting; however, further evi- 2. The CDC and the working group utilized emerging dence is needed of their preventability and research on objective surveillance definitions to de- comparability between institutions before rec- velop VAE definitions for adults.10-13,40,41 ommending their adoption for public reporting a. Objective definitions predicated on sustained in- or benchmarking.
creases in ventilator settings after a period of sta- v. Possible and probable VAP were developed for bility detect a range of clinically significant events, healthcare facilities to use for internal quality including VAP, pulmonary edema, acute respira- improvement purposes only. They are not suit- tory distress syndrome, and atelectasis.10,12 They able for public reporting or benchmarking be- consistently predict poor patient outcomes, in- cause clinicians and hospitals vary widely in cluding prolonged mechanical ventilation, in- when and how they acquire and process pul- creased length of stay in both the intensive care monary specimens from ventilated patients.
This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update vi. VAE definitions were designed for adult pa- lung injury. Qualitative analyses suggest that most VACs tients. More data are needed to inform whether are due to pneumonia, pulmonary edema, atelectasis, and how VAE can be adapted for surveillance and acute respiratory distress syndrome.10,12,15 Interven- in children and neonates.
tions that target these complications in particular and III. Recommended surveillance strategies interventions designed to shorten the duration of me- A. Hospitals are advised to conduct active surveillance for chanical ventilation in general may therefore be effective VAE, using CDC definitions and surveillance proto- strategies to lower VAE rates. These could include min- cols.43 The CDC's VAE module requires surveillance for imizing the use of sedatives, paired daily spontaneous all definition tiers (VAC, IVAC, possible VAP, and prob- awakening and breathing trials, early mobility, endo- tracheal tubes with subglottic secretion drainage ports, 1. Infection preventionists should work with their crit- low tidal volume ventilation, intermittent recruitment ical care, respiratory therapy, and/or information maneuvers, conservative fluid management, and re- technology staff to develop efficient means to gather strictive transfusion thresholds.46-54 Studies evaluating and aggregate ventilator data (daily minimum PEEP the impact of these and other interventions on VAE and daily minimum Fio ) from all patients ventilated rates are needed.
for greater than or equal to 4 days. Temperature, C. Until studies of the best strategies to prevent all VAEs white blood cell count, and antibiotic exposure data are published, the existing VAP prevention literature are needed only for the subset of patients who fulfill is the best available guide to improving outcomes for VAC criteria to determine if they fulfill IVAC criteria.
ventilated patients. Given the uncertainty surrounding Pulmonary specimen Gram stains and microbiology the accuracy and reproducibility of VAP diagnoses, test results are required only for the subset of patients however, we prioritize VAP interventions that have who meet IVAC criteria to determine if they fulfill been shown to improve objective outcomes, such as possible or probable VAP criteria.
duration of mechanical ventilation, intensive care or 2. Organizing daily ventilator data into "line lists" for hospital length of stay, mortality, and/or costs in ran- every patient, with 1 row of data per patient per cal- domized controlled trials. In addition, the potential endar day, facilitates VAC detection by allowing the benefits of different interventions are balanced against surveyor to vertically scan daily ventilator settings to their feasibility, costs, and potential harm. Recent re- look for sustained increases that cross the threshold views using this framework informed our recom- for VAC.44 Surveyors can also enter raw data into the CDC's online "VAE calculator" to assist with case iden-tification .
a. The VAE definitions are amenable to partial or complete automation using electronic data. Facil- Interventions that improve objective outcomes with little risk ities seeking to automate VAE detection should of harm are classified as basic practices that are suitable for work with their information technology personnel all hospitals. We also recommend interventions that are out- and/or electronic health record vendor(s).
come neutral but cost saving. Interventions that improve ob-jective outcomes but carry some risk of harm and interven- tions that lower VAP rates but for which insufficient data exist to determine their impact on objective outcomes areclassified as special approaches. Hospitals can consider adopt- I. Framework for evaluating and prioritizing interventions ing special approaches if their VAE rates do not improve A. Although VAE is now the CDC's recommended sur- despite high performance rates on basic practices. Interven- veillance metric for ventilated patients, almost all of the tions that improve neither VAP rates nor objective outcomes existing literature on VAP prevention is based on tra- are not recommended. The quality-of-evidence rating scheme ditional VAP definitions rather than VAE definitions.
is summarized in Table 1. Recommended strategies are sum- There are no data at present on the impact of traditional marized in Table 2 for adults, in Table 3 for preterm neonates, VAP prevention strategies on "probable pneumonias" and in Table 4 for infants and children.
(the closest proxy for VAP in the VAE framework), andthere are very little data regarding their impact on VAC and IVAC.14,45 Of note, VAC and IVAC intentionally flagmore than just pneumonia; hence, interventions di- I. Basic practices to prevent VAP and other VAEs in adult rected solely against pneumonia may not be sufficient patients: interventions with little risk of harm that decrease to reduce VAE rates.
duration of mechanical ventilation, length of stay, mor- B. VAC may be a surveillance marker for nosocomial acute tality, and/or costs This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 Grading of the Quality of Evidence Highly confident that the true effect lies close to that of the estimated size and direction of the effect. Evidence is rated as high quality when there is a wide range of studies with no majorlimitations, there is little variation between studies, and the summary estimate has a narrowconfidence interval.
The true effect is likely to be close to the estimated size and direction of the effect, but there is a possibility that it is substantially different. Evidence is rated as moderate quality when thereare only a few studies and some have limitations but not major flaws, there is some variationbetween studies, or the confidence interval of the summary estimate is wide.
The true effect may be substantially different from the estimated size and direction of the effect.
Evidence is rated as low quality when supporting studies have major flaws, there is importantvariation between studies, the confidence interval of the summary estimate is very wide, orthere are no rigorous studies, only expert consensus.
Based on Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)239 and the Canadian Task Force on Preventive Health Care.240 A. Avoid intubation if possible mitigated the potential benefits of sedative inter- 1. Use noninvasive positive pressure ventilation (NIPPV) ruption in this trial.65 whenever feasible (quality of evidence: I).
3. Assess readiness to extubate once a day (spontaneous a. NIPPV can be beneficial for patients with acute breathing trials) in patients without contraindications hypercarbic or hypoxemic respiratory failure sec- (quality of evidence: I).47,66-68 ondary to chronic obstructive pulmonary disease a. Daily spontaneous breathing trials are associated or cardiogenic congestive heart failure.57-59 NIPPV with extubation 1–2 days earlier compared with for these indications may decrease VAP risk, shorten the duration of mechanical ventilation, de- 4. Pair spontaneous breathing trials with spontaneous crease length of stay, and lower mortality rates awakening trials (quality of evidence: I).48 compared with invasive ventilation. Use caution a. Patients are more likely to pass a spontaneous when considering NIPPV to manage impaired con- breathing trial and be extubated if they are max- sciousness, acute lung injury, acute respiratory dis- imally awake at the time of the breathing trial.
tress syndrome, severe hypoxemia, and severe ac- C. Maintain and improve physical conditioning idemia or when continuing NIPPV for patients 1. Provide early exercise and mobilization (quality of whose dyspnea or gas exchange fails to rapidly re- evidence: II).
spond to NIPPV. Use of NIPPV for these indica- a. Early exercise and mobilization speed extubation, tions may delay intubation and increase harm, in- decrease length of stay, and increase the rate of cluding death.59,60 return to independent function.49,70-77 B. Minimize sedation b. Financial modeling suggests that early mobility 1. Manage ventilated patients without sedatives when- programs may be cost saving.78 ever possible (quality of evidence: II).46 D. Minimize pooling of secretions above the endotracheal a. Preferentially use agents and strategies other than benzodiazepines to manage agitation, such as an- 1. Provide endotracheal tubes with subglottic secretion algesics for patients in pain, reassurance, antipsy- drainage ports for patients likely to require greater than chotics, dexmedetomidine, and propofol.61 48 or 72 hours of intubation (quality of evidence: II).
2. Interrupt sedation once a day (spontaneous awak- a. Intermittent and continuous drainage of subglottic ening trials) for patients without contraindications secretions has been studied in 13 randomized con- (quality of evidence: I).62,63 trolled trials. On meta-analysis, the use of endotra- a. Two randomized controlled trials found that daily cheal tubes with subglottic drainage reduced VAP sedative interruptions decreased net sedative ex- rates by 55%, mean duration of mechanical venti- posures and reduced the average duration of me- lation by 1.1 days, and intensive care length of stay chanical ventilation by 2–4 days.48,62 A third trial by 1.5 days.50 There was no impact on hospital length found no impact on duration of mechanical ven- of stay or mortality. One study found that subglottic tilation but used substantially higher doses of ben- secretion drainage was associated with less antibiotic zodiazepines compared with the first 2 trials and utilization, while a second did not.79,80 observed an increase in sedative use in the seda- b. Endotracheal tubes with subglottic secretion drain- tion-interruption group.64 These factors may have age may be cost saving.81,82 This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update c. Reductions in duration of mechanical ventilation a. Selective decontamination of the oropharynx with with subglottic secretion drainage appear to be lim- topical antibiotics or of the oropharynx and di- ited to patients expected to require greater than gestive tract with a combination of topic, oral, and 48–72 hours of mechanical ventilation.83 Endotra- parenteral antibiotics decreased mortality rates by cheal tubes with subglottic secretion drainage ports 14% and 17%, respectively, in a large cluster ran- are therefore recommended only as a basic practice domized trial conducted in the Netherlands.95 for patients likely to require greater than 48–72 b. This strategy has not yet been adopted by North hours of intubation. Identifying these patients in American centers, however, due to fear that it advance can be very difficult. Patients requiring might increase the risk of antibiotic-resistant in- emergency intubation in the hospital and preop- fections, including Clostridium difficile infections, erative patients at risk for prolonged mechanical especially in centers with high baseline rates of ventilation are reasonable candidates.
antimicrobial-resistant organisms. Most studies to d. Extubating patients to place a subglottic secretion date do not indicate an elevated short-term risk drainage endotracheal tube is not recommended.
for antimicrobial resistance, but long-term studies E. Elevate the head of the bed are lacking.99,100 Hospitals with high baseline rates 1. Elevate the head of the bed to 30⬚–45⬚ (quality of of antibiotic resistance are advised to await the evidence: III).
results of long-term studies of digestive decontam- a. Elevating the head of the bed has been evaluated ination in high-resistance environments before in only 3 randomized controlled trials enrolling 337 routinely adopting this strategy.
patients altogether.84-86 One trial reported a 76% B. Interventions that may lower VAP rates but for which decrease in VAP rates, whereas the other 2 found there are insufficient data at present to determine their no difference in VAP rates. Of note, the larger of impact on duration of mechanical ventilation, length the 2 negative studies achieved minimal difference of stay, and mortality in head-of-bed elevation between the intervention 1. Perform oral care with chlorhexidine (quality of evi- and control groups, thereby limiting this study's capacity to evaluate the effect of head-of-bed ele- a. Oral care with chlorhexidine has been studied in vation on VAP or other outcomes.85 Nonetheless, at least 16 randomized controlled trials and 9 meta- a meta-analysis pooling these 3 studies did find a analyses to date.98,101-108 The benefits of oral care significant impact on VAP.87 In addition, enteral with chlorhexidine appear to be most pronounced feeding in the supine position substantially in- in preventing postoperative respiratory tract infec- creases the risk of developing VAP.84 tions in cardiac-surgery patients.108-110 The data for b. There are insufficient data at present to determine non-cardiac-surgery patients are more equivocal.
the impact of head-of-bed elevation on duration Meta-analyses suggest that oral care with chlor- of mechanical ventilation or mortality, but given hexidine can reduce pneumonia rates in this pop- the simplicity, ubiquity, minimal risk, lack of cost, ulation by 10%–30%; however, there is no apparent and potential benefit of this intervention we clas- impact on average duration of mechanical venti- sify it as a basic practice while we await further lation, intensive care length of stay, or mor- F. Maintain ventilator circuits b. Routine oral care without chlorhexidine may be 1. Change the ventilator circuit only if visibly soiled or indicated for reasons other than VAP prevention.
malfunctioning (quality of evidence: I).
2. Administer prophylactic probiotics (quality of evi- a. Changing the ventilator circuit as needed rather than on a fixed schedule has no impact on VAP a. Four meta-analyses of randomized controlled trials rates or patient outcomes but decreases costs.88-91 have found an association between probiotics and 2. Follow CDC/Healthcare Infection Control Practices lower VAP rates.111-114 Three of the meta-analyses Advisory Committee guidelines for sterilization and reported on length of stay and mortality. Two found disinfection of respiratory care equipment (quality of a positive impact on intensive care length of stay, while the third did not.111,112,114 None detected a sig- II. Special approaches nificant impact on mortality rates. Probiotics should A. Interventions that decrease duration of mechanical ven- not be used in patients with compromised immune tilation, length of stay, and/or mortality but for which systems or gastrointestinal diseases that increase the insufficient data on possible risks are available risk of gut translocation. There are multiple case 1. Use selective decontamination of the oropharynx to reports of fungemia or bacteremia in patients ad- decrease the microbial burden of the aerodigestive ministered probiotics and case reports of aerosol tract (quality of evidence: I).93-98 transmission of probiotics within ICUs.115-119 This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 Summary of Recommendations for Preventing Ventilator-Associated Pneumonia (VAP) in Adult Patients Good evidence that the intervention Use noninvasive positive pressure ventilation in decreases the average duration of mechanical ventilation, length of Manage patients without sedation whenever possible46,61 stay, mortality, and/or costs; benefits Interrupt sedation daily62 likely outweigh risks Assess readiness to extubate daily47,66-68 Perform spontaneous breathing trials with sedatives Facilitate early mobility49,70-75,78 Utilize endotracheal tubes with subglottic secretion drainage ports for patients expected to require greaterthan 48 or 72 hours of mechanical ventilation50 Change the ventilator circuit only if visibly soiled or Elevate the head of the bed to 30⬚–45⬚84-86 Special approaches Good evidence that the intervention Selective oral or digestive decontamination93-96 improves outcomes but insufficientdata available on possible risks May lower VAP rates but insufficient Regular oral care with chlorhexidine98,101-104 data to determine impact on dura- tion of mechanical ventilation, length Ultrathin polyurethane endotracheal tube cuffs120,121 of stay, or mortality Automated control of endotracheal tube cuff Saline instillation before tracheal suctioning124 Mechanical tooth brushing125,126 Lowers VAP rates but ample data sug- Silver-coated endotracheal tubes127 gest no impact on duration of me- chanical ventilation, length of stay, No impact on VAP rates, average dura- Stress ulcer prophylaxis135,136 tion of mechanical ventilation, length Early tracheotomy137 of stay, or mortalityc Monitoring residual gastric volumes138 Early parenteral nutrition139 No recommendation No impact on VAP rates or other pa- Closed/in-line endotracheal suctioning141-143 tient outcomes, unclear impact oncosts a There are very little data on head-of-bed elevation, but it is classified as a basic practice because of its simplicity, ubiquity, low cost, andpotential benefit.
b There are abundant data on the benefits of digestive decontamination but insufficient data on the long-term impact of this strategy onantimicrobial resistance rates.
c May be indicated for reasons other than VAP prevention.
3. Use ultrathin polyurethane endotracheal tube cuffs pressure (quality of evidence: III).
(quality of evidence: III).
a. Automated control of endotracheal tube cuff pres- a. Ultrathin polyurethane cuffs seal more uniformly sure led to lower VAP rates in one trial but not in against the tracheal wall and may therefore allow another.122,123 Neither trial detected an impact on fewer secretions to seep around the cuff and into duration of mechanical ventilation, length of stay, the lungs. Two studies reported lower VAP rates but or mortality.
were underpowered to assess other outcomes.120,121 5. Instill saline before tracheal suctioning (quality of 4. Provide automated control of endotracheal tube cuff evidence: III).
This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update a. One randomized trial in oncology patients found 2. Early tracheotomy (quality of evidence: I).
that saline instillation before tracheal suctioning a. Early versus late tracheotomy had no impact on lowered the rate of microbiologically confirmed VAP rates, duration of mechanical ventilation, or VAP but had no impact on clinical VAP rates or mortality risk on meta-analysis of 7 randomized patient outcomes.124 controlled trials.137 6. Provide mechanical tooth brushing (quality of evi- 3. Monitoring residual gastric volumes (quality of evi- dence: III).
a. One small randomized controlled trial suggested a. Monitoring patients for regurgitation and vomiting that tooth brushing can lower VAP rates, but a meta- alone is as effective as monitoring patients for re- analysis of 4 trials did not detect a significant impact gurgitation, vomiting, and residual gastric volumes on VAP risk, duration of mechanical ventilation, in- with regard to VAP rates, duration of mechanical tensive care length of stay, or mortality.125,126 ventilation, and mortality.138 III. Approaches that are generally not recommended for rou- 4. Early parenteral nutrition (quality of evidence: II).
tine VAP prevention a. Initiation of parenteral nutrition in critically ill pa- A. Generally not recommended for VAP prevention: in- tients within 48 hours of ICU admission is asso- terventions that may lower VAP rates but good-quality ciated with an increased risk of nosocomial infec- evidence suggests no impact on duration of mechanical tions and mortality compared with initiating ventilation, length of stay, or mortality parenteral nutrition on or after 8 days.139 1. Silver-coated endotracheal tubes (quality of evidence: a. A large, multicenter randomized controlled trial A. Interventions with no impact on VAP rates or patient found that silver-coated endotracheal tubes re- outcomes and unclear impact on costs duced VAP rates by 36% but found no impact on 1. Closed endotracheal tube suctioning systems (quality mean duration of mechanical ventilation, hospital of evidence: II).
length of stay, or mortality.127 a. Meta-analyses have found no difference in VAP 2. Kinetic beds (continuous lateral rotational therapy rates, duration of mechanical ventilation, intensive and oscillation therapy; quality of evidence: II).
care length of stay, or mortality between patients a. A meta-analysis of 15 randomized controlled trials randomized to open versus closed endotracheal suc- found a significant decrease in VAP rates but no tioning systems.140-142 A crossover trial in 4 ICUs impact on duration of mechanical ventilation or found no difference between open versus closed sys- mortality.128 The meta-analysis authors warned that tems in patient-to-patient transmissions of gram- the observed reduction in VAP rates might be ar- negative pathogens.143 Different trials have reached tifactual given weaknesses in contributing studies' different conclusions regarding cost.141,144,145 design and execution.
3. Prone positioning (quality of evidence: II).
a. Placing patients in the prone position is contro- Framework for evaluating and prioritizing interventions.
versial. Most meta-analyses suggest a borderline few studies in neonates evaluate the impact of VAP prevention effect on VAP rates and no impact on objective interventions on duration of mechanical ventilation, length outcomes, except among patients with severe acute of stay, or mortality. We therefore evaluated potential inter- respiratory distress syndrome.87,129-134 ventions solely on the basis of safety, feasibility, and potential B. Definitively not recommended for VAP prevention: in- impact on VAP rates. Interventions that lower VAP rates and terventions with good-quality evidence suggesting that confer minimal risks of harm are classified as basic practices.
they neither lower VAP rates nor decrease duration of Interventions with unproven but potential impact on VAP mechanical ventilation, length of stay, or mortality.
rates and minimal risk of harm are classified as special ap- 1. Stress ulcer prophylaxis (quality of evidence: II).
proaches. Hospitals can consider special approaches if their a. Stress ulcer prophylaxis lowers the risk of gastro- VAP rates do not improve despite high performance rates for intestinal bleeding, but meta-analyses suggest that basic practices. Interventions with unknown benefits, known there is no impact on nosocomial pneumonia rates, risks of harm, or unknown risks of harm are not recom- length of stay, or mortality.135,136 Effects may differ in patients receiving enteral nutrition: gastrointes- Specific considerations in preterm neonates.
tinal bleeding is less likely, and stress ulcer pro- used to diagnose VAP in adults have limited utility in preterm phylaxis may increase the risk of nosocomial pneu- neonates. Fever rarely occurs in preterm neonates, since they monia and mortality.135 are prone to hypothermia and are therefore often thermo- b. Stress ulcer prophylaxis may be indicated for rea- regulated with incubators or radiant heaters. Worsening gas sons other than VAP prevention.
exchange or apnea can be caused by significant nonpulmon- This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 Summary of Recommendations for Preventing Ventilator-Associated Pneumonia (VAP) in Preterm Neonates May lower VAP rates and minimal Use noninvasive positive pressure ventilation in risks of harm; benefits likely out- weigh potential risks Minimize the duration of mechanical ventilation Assess readiness to extubate daily Manage patients without sedation whenever Avoid unplanned extubation152 Provide regular oral care with sterile water Minimize breaks in the ventilator circuit Change the ventilator circuit only if visibly soiled or Special approaches Unknown impact on VAP rates, but Lateral recumbent positioning155 risk of harm likely minimal; reason- Reverse Trendelenburg positioning able to consider implementing if Closed/in-line suctioning systems156,157 rates remain elevated despite basicpractices Unknown impact on VAP rates and in- Regular oral care with antiseptics adequate data on risks May be harmful; risk-benefit balance Histamine 2 receptor antagonists158,159 does not favor intervention unless Prophylactic broad-spectrum antibiotics160-163 specifically indicated for reasons Daily spontaneous breathing trials165,166 other than VAP prevention Daily sedative interruptions Not recommended because appropriate Prophylactic probiotics or synbiotics167,168 products are not available or ap- Endotracheal tubes with subglottic secretion drainage proved for use in this population Silver-coated endotracheal tubes NA, none available.
ary illnesses, including sepsis and necrotizing enterocolitis.
a. Many premature neonates can be successfully sup- New or progressive infiltrates often indicate progression of ported with NIPPV.
chronic lung disease rather than new infection.
B. Minimize the duration of mechanical ventilation Pooled mean VAP rates for neonates reported to the CDC's 1. Manage patients without sedation whenever possible National Healthcare Safety Network (NHSN) vary from 0.2 (quality of evidence: III).150,151 to 1.8 infections per 1,000 ventilator days.146 It is not known 2. Assess readiness to extubate daily (quality of evidence: whether these rates are broadly representative of all neonatal units, however, since many hospitals do not perform VAP 3. Avoid unplanned extubations and reintubations surveillance for neonates in light of the limitations of VAP (quality of evidence: III).152 4. Provide regular oral care with sterile water (extrap- The CDC has not yet developed VAE definitions for neo- olated from studies in adults, no data in preterm nates. Adult VAE definitions are not suitable for neonates, as neonates; quality of evidence: III).
they do not reflect standard ventilator management practices 5. Minimize breaks in the ventilator circuit (extrapo- for this population.
lated from studies in adults, no data in preterm neo- I. Basic practices for preterm neonates: interventions with nates; quality of evidence: III).
minimal risk of harm that may lower VAP rates 6. Change the ventilator circuit only if visibly soiled or A. Avoid intubation if possible malfunctioning (extrapolated from studies in adults 1. Consider nasal continuous positive airway pressure and children, no data in preterm neonates; quality of ventilation with or without nasal intermittent me- evidence: III).153,154 chanical ventilation as an alternative to intubation II. Special approaches for preterm neonates (quality of evidence: I).147-149 A. Interventions with minimal risks of harm but unknown This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update impact on VAP rates as in preterm neonates and adults. The CDC has convened 1. Lateral recumbent positioning (quality of evidence: a working group to consider whether modified VAE defini- tions might be suitable for infants and children.
2. Reverse Trendelenburg positioning (quality of evi- Risk factors for VAP in infants and children are similar to dence: III).
those of adults.172-176 Once they develop teeth, children's oral 3. Closed/in-line flora are similar to those of adults.177,178 In general, most VAP prevention interventions recom- III. Generally not recommended mended for adults are presumed to be applicable to infants A. Inadequate data on risks and unknown impact on VAP and children. Some interventions recommended for adults, rates in preterm neonates however, are not available for infants and small children. For 1. Regular oral care with antiseptic (quality of evidence: example, some specialized endotracheal tubes are available only in larger sizes.
a. There are insufficient data on the impact of altering I. Basic practices for pediatric patients: interventions with neonatal microflora and whether oral antiseptics minimal risk of harm and some data that they lower VAP are absorbed across the oral mucosa of preterm A. Avoid intubation if possible B. May be harmful to preterm neonates 1. Use NIPPV in selected populations whenever feasible 1. Histamine H2-receptor antagonists may increase the (quality of evidence: II).
risk of nosocomial infection and mortality in preterm a. Risks of NIPPV in pediatric patients mirror those neonates (quality of evidence: II).158,159 for adults listed above in section I.A.1.A, with the 2. Prophylactic broad-spectrum antibiotics are associ- added issue that pediatric patients often need se- ated with increased risk of necrotizing enterocolitis, dation to tolerate NIPPV.179,180 prolonged length of stay, and death in premature in-fants (quality of evidence: II).160-163 B. Minimize the duration of mechanical ventilation 3. Spontaneous breathing trials (quality of evidence: 1. Assess readiness to extubate daily in patients without contraindications (quality of evidence: II).181-183 a. Ventilating preterm neonates with prolonged con- a. A randomized controlled trial in Brazil reported tinuous positive airway pressure alone increases the that daily spontaneous breathing trials decreased risk of extubation failure.164-166 the mean duration of ventilation.183 There is no C. Not applicable to preterm neonates consensus on the most effective technique for 1. Daily interruption of sedation (quality of evidence: spontaneous breathing trials in pediatric pa- a. Sedation is not routinely required for neonates on 2. Avoid unplanned extubations and reintubations (quality of evidence: III).185 b. There are no data on the impact of interrupting C. Provide regular oral care sedatives when sedation is used.
1. Provide regular oral care (quality of evidence: III).
2. Prophylactic probiotics and synbiotics (quality of evi- a. Two before-after studies of VAP bundles that dence: III).
emphasized oral care found decreases in VAP a. There are currently no products approved by the US Food and Drug Administration for preterm b. The American Dental Association recommends be- neonates. Limited data suggest that these may ben- ginning oral hygiene a few days after birth.187 Wipe efit some patients, but there are also multiple case the gums with a gauze pad after each feeding to reports of Lactobacillus bacteremia in infants and remove plaque and residual formula that could children following probiotic therapy.167-171 harm erupting teeth. When teeth erupt, brush 3. Endotracheal tubes equipped with subglottic secre- them gently twice a day with a child's size tooth- tion drains; suitably sized products are not commer- brush and water. Fluoride toothpaste is recom- cially available (quality of evidence: none available).
mended from 2 years of age onward. After oral 4. Silver-coated endotracheal tubes; suitably sized prod- hygiene, rinse and suction the mouth. Keep the ucts are not commercially available (quality of evi- oral mucosa and lips clean, moist, and intact using dence: none available).
sponge-tipped applicators dipped in nonalcohol,nonperoxide mouth rinse.186 D. Elevate the head of the bed 1. Elevate the head of the bed unless medically contra- Framework for evaluating and prioritizing interventions.
indicated (quality of evidence: III).
agnosing VAP is as challenging in term infants and children a. One before-after study of a VAP bundle that in- This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 Summary of Recommendations for Preventing Ventilator-Associated Pneumonia (VAP) in Pediatric Patients Some data that the intervention lowers Use noninvasive positive pressure ventilation for VAP rates and minimal risks of harm; potential benefits likely out- Assess readiness to extubate daily using spontaneous weigh potential risks breathing trials in patients withoutcontraindications182,183 Avoid unplanned extubations185 Provide regular oral care (ie, toothbrushing or gauze if Elevate the head of the bed to 30⬚–45⬚173 Change ventilator circuits only if visibly soiled or Use cuffed endotracheal tubes189,190 Prevent condensate from reaching the patient173,188 Special approaches Unknown impact on VAP rates, but Interrupt sedation daily192 risk of harm likely minimal; reason- Prophylactic probiotics able to consider implementing if Utilize endotracheal tubes with subglottic secretion rates remain elevated despite basic drainage ports for older pediatric patients expected to require greater than 48 or 72 hours of mechanicalventilation50 Unknown impact on VAP rates and in- Systemic antimicrobial therapy for ventilator-associated adequate data on risks Selective oropharyngeal or digestive decontamination No impact on VAP ratesa Oral care with antiseptics, such as chlorhexidine193,195 Stress ulcer prophylaxis199,200 Early tracheotomy Lowers VAP rates in adults, but no im- Silver-coated endotracheal tubes pact on duration of mechanical ven-tilation, length of stay, or mortality No recommendation Limited data on pediatric patients; no impact on VAP rates or outcomes inadults; unclear impact on costs a May, however, be indicated for reasons other than VAP prevention.
cluded head-of-bed elevation observed a decrease quently (quality of evidence: III).
a. Avoid draining the condensate toward the pa- b. Many hospital cribs do not have inbuilt angle-mea- suring devices. Alternative measuring devices are 3. Suction oral secretions before each position change required in these circumstances.
(quality of evidence: III).188 E. Maintain ventilator circuits F. Endotracheal tube selection and maintenance 1. Change ventilator circuits only when visibly soiled or 1. Use cuffed endotracheal tubes (quality of evidence: malfunctioning (quality of evidence: II).
a. One randomized trial and 1 observational study a. Pediatric intensivists have historically favored un- found no difference in VAP rates or mortality with cuffed tubes due to concern that cuffs may induce 3-day versus 7-day circuit changes. Circuit subglottic stenosis in pediatric airways. Cuffing has changes are therefore recommended only when been proven safe, however, and may decrease the the circuit is soiled or malfunctioning, to mini- risk of microaspiration.189,190 Cuffed tubes are now mize costs.153,154 used routinely for term newborns and children.191 2. Remove condensate from the ventilator circuit fre- 2. Maintain cuff pressure and volume at the minimal This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update occlusive settings to prevent clinically significant air 2. Stress ulcer prophylaxis (quality of evidence: III).
leaks around the endotracheal tube, typically 20 cm a. Two small studies found no impact on VAP of water (quality of evidence: III).123,189 a. The potential merits of automated manometers for 3. Early tracheotomy (quality of evidence: III).
VAP prevention have not been studied in pediatric 4. Thromboembolism prophylaxis (quality of evidence: II. Special approaches for pediatric patients C. Lowers VAP rates but no impact on duration of me- A. Interventions with evidence of benefit in adult pa- chanical ventilation, length of stay, or mortality tients and minimal risks of harm but limited data in pe- 1. Silver-coated endotracheal tubes (quality of evidence: diatric populations 1. Interrupt sedation once a day (quality of evidence: IV. No recommendation: limited data from pediatric studies, no impact on VAP rates or outcomes in adults, unclear a. Daily sedative interruptions decreased duration of mechanical ventilation and intensive care length of A. Closed/in-line suctioning stay without increases in adverse event rates in 1 1. An observational study of open versus closed suc- small randomized controlled trial.192 tioning in children did not find any difference in VAP b. There is nonetheless concern that sedative inter- rates, length of stay, or mortality, but the significance ruptions will increase the frequency of unplanned of these findings are unclear given the lack of blinding extubations and reintubations in younger patients, and randomization (quality of evidence: III).201 so this practice may be safest in older pediatricpatients. More data are needed.
2. Administer prophylactic probiotics (quality of evi- dence: III).
I. Internal reporting a. This recommendation is inferred from adult data A. Regular monitoring and internal reporting of patient but should be considered with caution due to outcomes and adherence rates to recommended pre- sparse safety data in pediatric patients and case vention strategies ("process measures") are important reports of Lactobacillus bacteremia associated with quality improvement strategies.
probiotic therapy, including cases in children with- B. Both outcome and process measure reporting are likely out known immunodeficiency.111-114,169-171 beneficial: improving outcomes is the primary goal of 3. Use endotracheal tubes with subglottic secretion care improvement programs, but analyzing perfor- drainage ports (quality of evidence: III).
mance rates for key processes of care may help identify a. This intervention is feasible only for children aged specific processes to target for improvement.
greater than or equal to 10 years since the smallest C. Report process and outcome measures to key organi- available endotracheal tube with subglottic secre- zational stakeholders, including frontline care provid- tion drainage ports is size 6.0.
ers, respiratory therapy directors, nursing and medical III. Generally not recommended for pediatric patients leaders, and senior hospital administrators. Feeding A. Unknown impact on VAP rates and/or inadequate data these data back to providers and leaders has been as- sociated with improvements in both performance rates 1. Systemic antimicrobial therapy for ventilator-asso- and outcomes.202-207 ciated tracheobronchitis (quality of evidence: III).
D. Report process measures internally only. External re- a. One retrospective study found that prolonged an- porting of process measure data is not appropriate at tibiotics for tracheobronchitis did not protect this time given substantial variability in the ways dif- against VAP but did increase the prevalence of mul- ferent organizations define, collect, analyze, and present process measure data.
2. Selective oropharyngeal or digestive decontamination E. There are insufficient data at present to guide the def- (quality of evidence: III).
inition and implementation of process measures for the a. See comments in section on adults.
prevention of VAP in neonatal and pediatric units.
B. No impact on VAP rates (these interventions may, how- II. Process measures ever, be indicated for reasons other than VAP A. Process measure definitions and measurement strate- 1. Oral care with chlorhexidine (quality of evidence: II).
1. For organizations that collect and report process mea- a. Chlorhexidine appears to be safe for developing sures, clearly define measures, including data sources, teeth,194 but randomized controlled trials have inclusion and exclusion criteria, frequency of mon- found no difference in VAP rates, length of stay, itoring, and numerator and denominator criteria.
or mortality in infants and children.193,195-198 2. Develop a formal system to document compliance.
This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 a. Compliance can be measured via direct observa- (a) Girard et al48 defined this as the percentage tions or via audits of patient charts, bedside pa- of sedative-days (ventilator-days during perwork, and/or electronic medical records. Peri- which sedatives are administered) on which odically validate the accuracy of paper and/or sedative and analgesic continuous infusions were interrupted or where at least 1 sched- 3. Perform assessments regularly.
uled dose of an intermittently prescribed a. The optimal frequency of assessments (eg, once sedative or analgesic was withheld.
daily, twice daily, or weekly) is not known, but the (b) Berenholtz et al207 defined this as the per- frequency can likely be adjusted on the basis of centage of ventilator-days on which patients compliance rates (eg, as compliance improves, less prescribed any sedative medications were frequent observations may be sufficient).
able to follow commands at least once dur- B. Prevention bundles ing the course of the day.
1. Consider combining a core set of critical process mea- b. Inclusion criteria: all patients on mechanical sures together into a bundle to enhance care. Bundling ventilation being treated with 1 or more of the care processes facilitates implementation by providing following drugs: lorazepam, midazolam, pro- a clear, tangible set of expectations to follow. In ad- pofol, fentanyl, morphine, meperidine, hydro- dition, some care processes may be synergistic.
morphone, or dexmedetomidine.207 2. There is no consensus on which care processes to c. Exclusion criteria: patients receiving a sedative include in a VAP prevention bundle. There is sub- infusion for active seizures or alcohol with- stantial heterogeneity in different hospitals' ventilator drawal, escalating sedative doses due to ongoing agitation, neuromuscular blockade, evidence of 3. Evidence on the impact of bundles is limited. Many active myocardial ischemia within the previous prevention bundles have been associated with variable 24 hours, evidence of increased intracranial reductions in VAP rates. A smaller subset has been associated with improvements in objective out- 3. Expedite extubation comes.209-214 To date, however, prevention bundles A. Perform spontaneous breathing trials daily have been tested only in observational before-after and time-series analyses rather than in randomized i. Percentage of ventilator-days on which pa- controlled trials. It is therefore difficult to disentangle tients received a trial of spontaneous venti- the extent to which lower VAP rates and better out- lation. A trial of spontaneous breathing is de- comes are due to prevention bundles versus secular fined as a period of time where ventilatory trends in severity of illness, advances in medical care, support is removed. This can be done by al- and ascertainment biases.
lowing the patient to 4. Compliance can be reported for each process measure (a) Breathe through a T-tube circuit individually and/or as all-or-none compliance with a (b) Breathe through a ventilator circuit using bundle of process measures. For all-or-none com- "flow triggering" with continuous positive pliance, credit is given only if all components have airway pressure of 0–5 cm of water and/ been accomplished and documented; if any com- or pressure support ventilation with 5–8 ponents were not performed and/or were not doc- cm of water.48,207,217 umented, no credit is given.212,215 ii. The initial spontaneous breathing trial should III. Approaches to defining process measures last at least 30 minutes.
A. There is no consensus on how best to define adherence b. Inclusion criteria: all patients on mechanical to different process measures. Examples of how differ- ent organizations have defined selected process mea- c. Exclusion criteria: oxygen saturation less than sures are summarized below. These examples are pri- 88%, Fio greater than 50%, PEEP greater than marily drawn from multicenter quality improvement 8 cm of water, lack of spontaneous breathing effort for greater than or equal to 5 minutes, 1. Optimize hand hygiene agitation, active myocardial ischemia, significant a. Readers are referred to the Compendium article vasopressor requirement, increased intracranial "Strategies to Prevent Healthcare-Associated Infec- pressure, moribund state with death likely tions through Hand Hygiene"216 for a comprehen- sive discussion of this topic.
4. Minimize the risk of aspiration 2. Minimize sedation a. Elevate the head of the bed a. Perform spontaneous awakening trials daily.
i. Definitions i. Definitions (a) Berenholtz et al207 defined this as the per- This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update centage of ventilator-days on which the head iii. Multiply by 1,000 and express as the overall of the bed is elevated 30⬚–45⬚.
VAP rate per 1,000 ventilator-days.
(b) Bloos et al213 had access to continuous elec- c. Probable VAP rate tronic monitoring of their beds' backrest el- i. Numerator: total number of all probable VAP evation angles. They therefore defined head- of-bed elevation compliance as the mean ii. Denominator: total ventilator-days.
daily backrest elevation angle.
iii. Multiply by 1,000 and express as the probable (c) Sinuff et al214 tracked concordance with VAP rate per 1,000 ventilator-days.
head-of-bed elevation to 45⬚. They defined V. External reporting concordance as the sum of days on which A. VAC and IVAC are potentially appropriate metrics for the head of the bed was elevated plus the public reporting, interfacility comparison, and pay-for- days on which head-of-bed elevation was performance programs. Better data on their respon- contraindicated divided by total ventilator- siveness to quality improvement programs are neces- days. They encouraged providers to consider elevating the head of the bed as much as interfacility comparisons or pay-for-performance pro- possible when elevation to 45⬚ was not grams. Suitable risk-adjustment strategies are also ii. Inclusion criteria: all patients on mechanical B. Possible and probable VAP are not suitable for external reporting at this time since substantial variability in iii. Exclusion criteria: patients with hemodynamic clinical and laboratory practices in the acquisition, pro- instability, undergoing resuscitation, unstable cessing, and interpretation of culture data preclude spine or not cleared, pelvic instability or frac- tures, prone position, intra-aortic balloon pump in femoral vessels, and obesity procedures.214 C. VAP rates generated using NHSN's former surveillance IV. Outcome measures definitions are not appropriate for external reporting A. Conduct surveillance for all VAEs, including VAC, in light of their considerable subjectivity.
IVAC, possible VAP, and probable VAP in adult ICUs.
D. Hospitals in states that have mandatory reporting laws Report rates for all events included in the algorithm.
must collect and report data as required by their state.
VAE definitions are not currently available for pediatric Local and state health departments can provide specific and neonatal patients; hence, these units should con- information on public reporting requirements.
tinue to use traditional NHSN VAP definitions.
1. VAE incidence density a. Numerator: total number of VACs, including IVACs, possible VAPs, and probable VAPs.
b. Denominator: total ventilator-days.
Accountability is an essential principle for preventing HAIs.
c. Multiply by 1,000 and express as VAEs per 1,000 It provides the necessary translational link between science and implementation. Without clear accountability, scientifi- d. Note that the total VAE rate is synonymous with cally based implementation strategies will be used in an in- the total VAC rate.
consistent and fragmented way, decreasing their effectiveness 2. IVAC incidence density in preventing HAIs. Accountability begins with the chief ex- a. Numerator: total number of IVACs, including pos- ecutive officer and other senior leaders who provide the im- sible VAPs and probable VAPs.
perative for HAI prevention, thereby making HAI prevention b. Denominator: total ventilator-days.
an organizational priority. Senior leadership is accountable c. Multiply by 1,000 and express as the IVAC rate per for providing adequate resources needed for effective imple- mentation of an HAI prevention program. These resources 3. VAP incidence density include necessary personnel (clinical and nonclinical), edu- a. Organizations can consider calculating both their cation, and equipment (Table 5).
total VAP rate (sum of possible and probable VAPs) Engagement, education, execution, and evaluation are fur- and their probable VAP rate for internal monitor- ther common attributes of successful care improvement pro- ing purposes. The former metric is presumed to grams.203 These attributes are elaborated below.
be more sensitive, the latter more specific.
b. Total VAP rate i. Numerator: total number of all possible and A. Develop a multidisciplinary team probable VAPs.
1. Multidisciplinary teams set goals, define each step in ii. Denominator: total ventilator-days.
the implementation process, and monitor progress in This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 Fundamental Elements of Accountability for Healthcare-Associated Infection Prevention Senior management is responsible for ensuring that the healthcare system supports an infection prevention and control (IPC) pro- gram that effectively prevents healthcare-associated infections (HAIs) and the transmission of epidemiologically importantpathogens Senior management is accountable for ensuring that an adequate number of trained personnel are assigned to the IPC program and adequate staffing of other departments that play a key role in HAI prevention (eg, environmental services) Senior management is accountable for ensuring that healthcare personnel, including licensed and nonlicensed personnel, are ade- quately trained and competent to perform their job responsibilities Direct healthcare providers (such as physicians, nurses, aides, and therapists) and ancillary personnel (such as environmental service and equipment processing personnel) are responsible for ensuring that appropriate IPC practices are used at all times (includinghand hygiene, standard and isolation precautions, and cleaning and disinfection of equipment and the environment) Senior and unit leaders are responsible for holding personnel accountable for their actionsIPC leadership is responsible for ensuring that an active program to identify HAIs is implemented, that HAI data are analyzed and regularly provided to those who can use the information to improve the quality of care (eg, unit staff, clinicians, and hospitaladministrators), and that evidence-based practices are incorporated into the program Senior and unit leaders are accountable for ensuring that appropriate training and educational programs to prevent HAIs are devel- oped and provided to personnel, patients, and families Personnel from the IPC program, the laboratory, and information technology departments are responsible for ensuring that systems are in place to support the surveillance program reaching goals.173,218,219 Programs developed by team learn from best practices, brainstorm solutions to com- consensus are more effective and increase guideline mon problems, and promulgate local successes.227 adherence.173,218,220 Multidisciplinary teams include representatives from all disciplines that care for ven- A. Provide education sessions tilated patients, including, at a minimum, unit di- 1. Education sessions help summarize evidence, explain rectors, physicians, nurses, and respiratory therapists.
new processes, set expectations, and encourage staff Other partners who can strengthen the team include to adopt recommended practices.202,228 Education ses- infection preventionists, pharmacists, nutritionists, sions can include workshops, hands-on trainings, physical therapists, occupational therapists, family conferences, slide presentations, and/or interactive members, and patient advocates.207,219,221,222 discussions; employing multiple teaching modalities B. Involve local champions can help meet diverse learning styles.224,229,230 Both lo- 1. Identify local champions, including formal (eg, med- cal champions and topic experts (eg, infection pre- ical director, nursing director, charge nurses, director ventionists) can lead staff education.173,226 of respiratory therapy) and informal (eg, engaged 2. Education sessions must be informative and relevant frontline staff) leaders.207,213,219,221-223 for the learner; therefore, it is important to have mul- 2. Local champions are important to success because they tidisciplinary educational programs customized for engage stakeholders, educate peers, encourage ongoing improvement, and increase buy-in and ownership by 3. Ongoing staff education helps maintain high levels both staff and administrators.173,203,207,220,223,224 of compliance with recommended practices.205,230 3. Local champions should know their hospital's inter- 4. Educating patients and family members may help ests and needs, be able to shape strategies to match them better engage with and support the medical local unit culture, monitor progress, and facilitate team's plan of care.
necessary changes during implementation.202 Early B. Provide educational materials and continual communication between local cham- 1. Provide educational materials to staff that summarize pions and frontline staff allows providers to ask ques- the evidence, support self-study, and remind staff tions, resolve concerns, prepare for action, and sus- about new practices.231 Examples of educational ma- terials include pocket cards, brochures, posters, fact C. Utilize peer networks sheets, daily guides, guideline summaries, flow sheets 1. Horizontal networking of peers across hospitals can and 1-page bulletins.173,205,207,227,229,232 promote and increase compliance with evidence-based best practices. Voluntary peer networks encourage col- A. Standardize care processes laboration, analysis of performance, accountability, 1. Standardize care processes through the implemen- and commitment to specific goals.207,225-227 Comparing tation of guidelines, bundles, protocols, or pathways.
progress and benchmarks between ICUs can help units Standardization helps establish new care processes as better understand their local strengths and weaknesses, "normal behaviors" for staff.202 This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM

strategies to prevent vap: 2014 update 2. Daily multidisciplinary rounds are widely advocated; these rounds should follow a structured format and S.S.M.—The findings and conclusions in this report are those include discussion about the patients' goals for the of the authors and do not necessarily represent the official position of the day, consideration of what resources and actions are Centers for Disease Control and Prevention.
Potential conflicts of interest. M.K. reports having received honoraria for necessary to achieve these goals, and identification of lectures from Premier Healthcare Alliance. L.R.G. reports having received potential barriers and/or safety issues.204,207,222 honoraria from Premier, Care Fusion, Infection Control Today, and Advanced B. Create redundancy Sterilization Products. R.B. reports having served as an advisor/consultant 1. Build redundancy or independent checks into care- for Covidien, Hamilton, Advanced Circulatory Systems, and Ikaria. E.C.E.,M.D.H., G.L., L.L.M., S.S.M., G.P.P., K.S., D.S.Y., and S.M.B. report no con- delivery processes to remind staff about new prac- flicts of interest.
tices.202,203,212 Redundancy can take the form of posters,bulletins, pens, stamps, pocket cards, 1-page signs, Address correspondence to Michael Klompas, MD, MPH, Department daily goals in patient rooms, checklists and preprinted of Population Medicine, Harvard Medical School and Harvard Pilgrim order sets, text messages, and screen savers on clinical Health Care Institute, 133 Brookline Avenue, 6th Floor, Boston, MA 02215 computers.203,205,212,226,232-235 Encourage family members to ask the care team if patients are receiving evidence-based therapies for VAP prevention.207 2. The combination of both education and reminders significantly improves processes of care.228,236 1. Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(suppl 1):S31–S40.
A. Measure performance 2. Yokoe DS, Andersen DJ, Berenholtz SM, et al. Introduction to 1. Measure performance using frequent formal and in- "A Compendium of Strategies to Prevent Healthcare-Associ- formal audits of clinical practice.203,237 ated Infections in Acute Care Hospitals: 2014 Updates." Infect 2. Measuring process and outcome measures enhances Control Hosp Epidemiol 2014;35(5):455–459.
awareness, establishes expectations, creates urgency, 3. Dudeck MA, Horan TC, Peterson KD, et al. National Health- care Safety Network (NHSN) report, data summary for 2010, and rewards changes in behavior.202 device-associated module. Am J Infect Control 2011;39(10): 3. Evaluating performance provides an ongoing, real- time image of actual implementation rates.234 4. Klompas M. Eight initiatives that misleadingly lower ventilator- 4. Areas of poor compliance can be rapidly identified associated pneumonia rates. Am J Infect Control 2012;40(5): and rectified.203,237 If compliance remains poor in one area, the improvement team should walk the process 5. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units.
with staff to gain additional insights into barriers to 6. Magill SS, Hellinger W, Cohen J, et al. Prevalence of healthcare- 5. Analyze all or a representative sample of VACs for associated infections in acute care hospitals in Jacksonville, etiology and preventability. Pneumonia, pulmonary Florida. Infect Control Hosp Epidemiol 2012;33(3):283–291.
edema, acute respiratory distress syndrome, and atel- 7. Thomas BW, Maxwell RA, Dart BW, et al. Errors in admin- ectasis are typical etiologies for VACs.10,12,15 Use your istrative-reported ventilator-associated pneumonia rates: are analyses to select and refine prevention strategies that never events really so? Am Surg 2011;77(8):998–1002.
8. Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison address the most frequent and preventable causes of of ventilator-associated pneumonia rates as identified accord- VACs in your clinical setting.
ing to the National Healthcare Safety Network and American B. Provide feedback to staff College of Chest Physicians criteria. Crit Care Med 2012;40(1): 1. Provide regular feedback on process and/or outcome data to staff.202,204,212,226,235 Feedback can be provided 9. Novosel TJ, Hodge LA, Weireter LJ, et al. Ventilator-associated via wall displays or during meetings.173,202,229,231 pneumonia: depends on your definition. Am Surg 2012;78(8):851–854.
2. Providing feedback helps staff appreciate how their 10. Klompas M, Khan Y, Kleinman K, et al. Multicenter evaluation efforts to improve are impacting performance rates of a novel surveillance paradigm for complications of me- and patients' outcomes. This helps maintain staff chanical ventilation. PLoS ONE 2011;6(3):e18062.
motivation and can boost adherence to new pro- 11. Klompas M, Magill S, Robicsek A, et al. Objective surveillance definitions for ventilator-associated pneumonia. Crit Care Med 3. Feedback is also important for future efforts because 12. Hayashi Y, Morisawa K, Klompas M, et al. Toward improved feedback helps pinpoint new areas for improvement surveillance: the impact of ventilator-associated complications and marks successful transitions to new standards of on length of stay and antibiotic use in patients in intensive care units. Clin Infect Dis 2013;56(4):471–477.
This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 13. Prospero E, Illuminati D, Marigliano A, et al. Learning from data fail to accurately identify cases of healthcare-associated Galileo: ventilator-associated pneumonia surveillance. Am J infection. Infect Control Hosp Epidemiol 2006;27(4):332–337.
Respir Crit Care Med 2012;186(12):1308–1309.
31. Stevenson KB, Khan Y, Dickman J, et al. Administrative coding 14. Muscedere J, Sinuff T, Heyland D, et al. The clinical impact data, compared with CDC/NHSN criteria, are poor indicators and preventability of ventilator-associated conditions in criti- of health care–associated infections. Am J Infect Control 2008; cally ill mechanically ventilated patients. Chest 2013;144(5): 32. Drees M, Hausman S, Rogers A, Freeman L, Frosch K, Wroten 15. Klein Klouwenberg PM, van Mourik MS, Ong DS, et al. Elec- K. Underestimating the impact of ventilator-associated pneu- tronic implementation of a novel surveillance paradigm for monia by use of surveillance data. Infect Control Hosp Epidemiol ventilator-associated events: feasibility and validation. Am J Respir Crit Care Med 2014;189(8):947–955.
33. Klompas M. The paradox of ventilator-associated pneumonia 16. Klompas M, Kleinman K, Murphy MV. Descriptive epidemi- prevention measures. Crit Care 2009;13(5):315.
ology and attributable morbidity of ventilator-associated 34. Bonten MJ. Ventilator-associated pneumonia: preventing the events. Infect Control Hosp Epidemiol 2014;35(5):502–510.
inevitable. Clin Infect Dis 2011;52(1):115–121.
17. Nguile-Makao M, Zahar JR, Francais A, et al. Attributable mor- 35. Klompas M, Platt R. Ventilator-associated pneumonia—the tality of ventilator-associated pneumonia: respective impact of wrong quality measure for benchmarking. Ann Intern Med main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models. Intensive 36. van Saene HK, Silvestri L, de la Cal MA, Baines P. The em- Care Med 2010;36(5):781–789.
peror's new clothes: the fairy tale continues. J Crit Care 2009; 18. Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mor- tality of ventilator associated pneumonia: a reappraisal using 37. Uckay I, Ahmed QA, Sax H, Pittet D. Ventilator-associated causal analysis. Am J Respir Crit Care Med 2011;184(10):1133– pneumonia as a quality indicator for patient safety? Clin Infect 19. Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating 38. Blot S, Lisboa T, Angles R, Rello J. Prevention of VAP: is zero the attributable mortality of ventilator-associated pneumonia rate possible? Clin Chest Med 2011;32(3):591–599.
from randomized prevention studies. Crit Care Med 2011; 39. Magill SS, Klompas M, Balk R, et al. Developing a new, national approach to surveillance for ventilator-associated events. Crit 20. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable Care Med 2013;41(11):2467–2475.
mortality of ventilator-associated pneumonia: a meta-analysis 40. Klompas M, Kleinman K, Platt R. Development of an algorithm of individual patient data from randomised prevention studies.
for surveillance of ventilator-associated pneumonia with elec- Lancet Infect Dis 2013;13(8):665–671.
tronic data and comparison of algorithm results with clinician 21. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and eco- diagnoses. Infect Control Hosp Epidemiol 2008;29(1):31–37.
nomic consequences of ventilator-associated pneumonia: a sys- 41. Klompas M, Kleinman K, Khan Y, et al. Rapid and reproducible tematic review. Crit Care Med 2005;33(10):2184–2193.
surveillance for ventilator-associated pneumonia. Clin Infect 22. Kirtland SH, Corley DE, Winterbauer RH, et al. The diagnosis of ventilator-associated pneumonia: a comparison of histologic, 42. Dessap AM, Katsahian S, Roche-Campo F, et al. Ventilator- microbiologic, and clinical criteria. Chest 1997;112(2):445–457.
associated pneumonia during weaning from mechanical ven- 23. Klompas M. Does this patient have ventilator-associated pneu- tilation: role of fluid management. Chest. doi:10.1378/chest.13 monia? JAMA 2007;297(14):1583–1593.
-2564. Electronically published March 20, 2014.
24. Wunderink RG, Woldenberg LS, Zeiss J, Day CM, Ciemins J, 43. Centers for Disease Control and Prevention (CDC). Ventilator- Lacher DA. The radiologic diagnosis of autopsy-proven ven- Associated Event Protocol. Atlanta: CDC, 2014. tilator-associated pneumonia. Chest 1992;101(2):458–463.
25. Tejerina E, Esteban A, Fernandez-Segoviano P, et al. Accuracy of clinical definitions of ventilator-associated pneumonia: com- March 25, 2014.
parison with autopsy findings. J Crit Care 2010;25(1):62–68.
44. Klompas M. Ventilator-associated events surveillance: a patient 26. Schurink CA, Van Nieuwenhoven CA, Jacobs JA, et al. Clinical safety opportunity. Curr Opin Crit Care 2013;19(5):424–431.
pulmonary infection score for ventilator-associated pneumo- 45. Lewis SC, Li L, Murphy MV, Klompas M. Risk factors for nia: accuracy and inter-observer variability. Intensive Care Med ventilator-associated events: a case-control multivariable anal- ysis. Crit Care Med. doi:10.1097/CCM.0000000000000338.
27. Klompas M. Interobserver variability in ventilator-associated Electronically published April 18, 2014.
pneumonia surveillance. Am J Infect Control 2010;38(3):237– 46. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a ran- 28. Klein Klouwenberg PM, Ong DS, Bos LD, et al. Interobserver domised trial. Lancet 2010;375(9713):475–480.
agreement of Centers for Disease Control and Prevention cri- 47. Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration teria for classifying infections in critically ill patients. Crit Care of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996;335(25):1864– 29. Stevens JP, Kachniarz B, Wright SB, et al. When policy gets it right: variability in U.S. hospitals' diagnosis of ventilator- 48. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a associated pneumonia. Crit Care Med 2014;42(3):497–503.
paired sedation and ventilator weaning protocol for mechan- 30. Sherman ER, Heydon KH, St. John KH, et al. Administrative ically ventilated patients in intensive care (Awakening and This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update Breathing Controlled trial): a randomised controlled trial.
trial of protocol-directed versus physician-directed weaning from mechanical ventilation. Crit Care Med 1997;25(4):567– 49. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early phys- ical and occupational therapy in mechanically ventilated, crit- 67. Marelich GP, Murin S, Battistella F, Inciardi J, Vierra T, Roby ically ill patients: a randomised controlled trial. Lancet 2009; M. Protocol weaning of mechanical ventilation in medical and surgical patients by respiratory care practitioners and nurses: 50. Muscedere J, Rewa O, McKechnie K, Jiang X, Laporta D, Hey- effect on weaning time and incidence of ventilator-associated land DK. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and 68. Lellouche F, Mancebo J, Jolliet P, et al. A multicenter random- meta-analysis. Crit Care Med 2011;39(8):1985–1991.
ized trial of computer-driven protocolized weaning from me- 51. Determann RM, Royakkers A, Wolthuis EK, et al. Ventilation chanical ventilation. Am J Respir Crit Care Med 2006;174(8): with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive 69. Esteban A, Frutos F, Tobin MJ, et al; Spanish Lung Failure randomized controlled trial. Crit Care 2010;14(1):R1.
Collaborative Group. A comparison of four methods of wean- 52. Futier E, Constantin J-M, Paugam-Burtz C, et al. A trial of ing patients from mechanical ventilation. N Engl J Med 1995; intraoperative low-tidal-volume ventilation in abdominal sur- gery. N Engl J Med 2013;369(5):428–437.
70. Hopkins RO, Spuhler VJ, Thomsen GE. Transforming ICU 53. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison culture to facilitate early mobility. Crit Care Clin 2007;23(1): of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354(24):2564–2575.
71. Morris PE, Goad A, Thompson C, et al. Early intensive care 54. Hebert PC, Wells G, Blajchman MA, et al; Transfusion Re- unit mobility therapy in the treatment of acute respiratory quirements in Critical Care Investigators, Canadian Critical failure. Crit Care Med 2008;36(8):2238–2243.
Care Trials Group. A multicenter, randomized, controlled clin- 72. Bailey P, Thomsen GE, Spuhler VJ, et al. Early activity is feasible ical trial of transfusion requirements in critical care. N Engl J and safe in respiratory failure patients. Crit Care Med 2007; 55. Klompas M. Prevention of ventilator-associated pneumonia.
73. Morris PE, Griffin L, Berry M, et al. Receiving early mobility Expert Rev Anti Infect Ther 2010;8(7):791–800.
during an intensive care unit admission is a predictor of im- 56. Bouadma L, Wolff M, Lucet JC. Ventilator-associated pneu- proved outcomes in acute respiratory failure. Am J Med Sci monia and its prevention. Curr Opin Infect Dis 2012;25(4): 74. Burtin C, Clerckx B, Robbeets C, et al. Early exercise in critically 57. Hess DR. Noninvasive positive-pressure ventilation and ven- ill patients enhances short-term functional recovery. Crit Care tilator-associated pneumonia. Respir Care 2005;50(7):924–929.
58. Burns KE, Adhikari NK, Keenan SP, Meade MO. Noninvasive 75. Needham DM, Korupolu R, Zanni JM, et al. Early physical positive pressure ventilation as a weaning strategy for intubated medicine and rehabilitation for patients with acute respiratory adults with respiratory failure. Cochrane Database Syst Rev failure: a quality improvement project. Arch Phys Med Rehabil 59. Carron M, Freo U, BaHammam AS, et al. Complications of 76. Titsworth WL, Hester J, Correia T, et al. The effect of increased non-invasive ventilation techniques: a comprehensive quali- mobility on morbidity in the neurointensive care unit. J Neu- tative review of randomized trials. Br J Anaesth 2013;110(6): 77. Balas MC, Vasilevskis EE, Olsen KM, et al. Effectiveness and 60. Aboussouan LS, Ricaurte B. Noninvasive positive pressure ven- safety of the awakening and breathing coordination, delirium tilation: increasing use in acute care. Cleve Clin J Med 2010; monitoring/management, and early exercise/mobility bundle.
61. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines Crit Care Med 2014;42(5):1024–1036.
for the management of pain, agitation, and delirium in adult 78. Lord RK, Mayhew CR, Korupolu R, et al. ICU early physical patients in the intensive care unit. Crit Care Med 2013;41(1): rehabilitation programs: financial modeling of cost savings. Crit Care Med 2013;41(3):717–724.
62. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interrup- 79. Bouza E, Perez MJ, Munoz P, Rincon C, Barrio JM, Hortal J.
tion of sedative infusions in critically ill patients undergoing Continuous aspiration of subglottic secretions in the preven- mechanical ventilation. N Engl J Med 2000;342(20):1471–1477.
tion of ventilator-associated pneumonia in the postoperative 63. Schweickert WD, Gehlbach BK, Pohlman AS, Hall JB, Kress period of major heart surgery. Chest 2008;134(5):938–946.
JP. Daily interruption of sedative infusions and complications 80. Lacherade JC, De Jonghe B, Guezennec P, et al. Intermittent of critical illness in mechanically ventilated patients. Crit Care subglottic secretion drainage and ventilator-associated pneu- monia: a multicenter trial. Am J Respir Crit Care Med 2010; 64. Mehta S, Burry L, Cook D, et al. Daily sedation interruption in mechanically ventilated critically ill patients cared for with 81. Shorr AF, O'Malley PG. Continuous subglottic suctioning for a sedation protocol. JAMA 2012:308(19):1985–1992.
the prevention of ventilator-associated pneumonia: potential 65. Kress JP, Hall JB. The changing landscape of ICU sedation.
economic implications. Chest 2001;119(1):228–235.
82. Hallais C, Merle V, Guitard PG, et al. Is continuous subglottic 66. Kollef MH, Shapiro SD, Silver P, et al. A randomized, controlled suctioning cost-effective for the prevention of ventilator- This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 associated pneumonia? Infect Control Hosp Epidemiol 2011; 97. de Smet AM, Kluytmans JA, Blok HE, et al. Selective digestive tract decontamination and selective oropharyngeal decontam- 83. Frost SA, Azeem A, Alexandrou E, et al. Subglottic secretion ination and antibiotic resistance in patients in intensive-care drainage for preventing ventilator associated pneumonia: a units: an open-label, clustered group-randomised, crossover meta-analysis. Aust Crit Care 2013;26(4):180–188.
study. Lancet Infect Dis 2011;11(5):372–380.
84. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, 98. Chan EY, Ruest A, Meade MO, Cook DJ. Oral decontamination Ferrer M. Supine body position as a risk factor for nosocomial for prevention of pneumonia in mechanically ventilated adults: pneumonia in mechanically ventilated patients: a randomised systematic review and meta-analysis. BMJ 2007;334(7599):889.
99. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH. Effect of 85. van Nieuwenhoven CA, Vandenbroucke-Grauls C, van Tiel FH, selective decontamination on antimicrobial resistance in in- et al. Feasibility and effects of the semirecumbent position to tensive care units: a systematic review and meta-analysis. Lancet prevent ventilator-associated pneumonia: a randomized study.
Infect Dis 2013;13(4):328–341.
Crit Care Med 2006;34(2):396–402.
100. van der Meer JW, Vandenbroucke-Grauls CM. Resistance to 86. Keeley L. Reducing the risk of ventilator-acquired pneumonia selective decontamination: the jury is still out. Lancet Infect Dis through head of bed elevation. Nurs Crit Care 2007;12(6):287– 101. Chlebicki MP, Safdar N. Topical chlorhexidine for prevention 87. Alexiou VG, Ierodiakonou V, Dimopoulos G, Falagas ME. Im- of ventilator-associated pneumonia: a meta-analysis. Crit Care pact of patient position on the incidence of ventilator-asso- ciated pneumonia: a meta-analysis of randomized controlled 102. Pileggi C, Bianco A, Flotta D, Nobile CG, Pavia M. Prevention trials. J Crit Care 2009;24(4):515–522.
of ventilator-associated pneumonia, mortality and all intensive 88. Dreyfuss D, Djedaini K, Weber P, et al. Prospective study of care unit acquired infections by topically applied antimicrobial nosocomial pneumonia and of patient and circuit colonization or antiseptic agents: a meta-analysis of randomized controlled during mechanical ventilation with circuit changes every 48 trials in intensive care units. Crit Care 2011;15(3):R155.
hours versus no change. Am Rev Respir Dis 1991;143(4 pt 1): 103. Labeau SO, Van de Vyver K, Brusselaers N, Vogelaers D, Blot SI. Prevention of ventilator-associated pneumonia with oral 89. Kollef MH, Shapiro SD, Fraser VJ, et al. Mechanical ventilation antiseptics: a systematic review and meta-analysis. Lancet Infect with or without 7-day circuit changes: a randomized controlled trial. Ann Intern Med 1995;123(3):168–174.
104. Tantipong H, Morkchareonpong C, Jaiyindee S, Thamlikitkul 90. Long MN, Wickstrom G, Grimes A, Benton CF, Belcher B, V. Randomized controlled trial and meta-analysis of oral de- Stamm AM. Prospective, randomized study of ventilator- contamination with 2% chlorhexidine solution for the pre- associated pneumonia in patients with one versus three ven- vention of ventilator-associated pneumonia. Infect Control tilator circuit changes per week. Infect Control Hosp Epidemiol Hosp Epidemiol 2008;29(2):131–136.
105. Li J, Xie D, Li A, Yue J. Oral topical decontamination for 91. Lorente L, Lecuona M, Galvan R, Ramos MJ, Mora ML, Sierra preventing ventilator-associated pneumonia: a systematic re- A. Periodically changing ventilator circuits is not necessary to view and meta-analysis of randomized controlled trials. J Hosp prevent ventilator-associated pneumonia when a heat and moisture exchanger is used. Infect Control Hosp Epidemiol 2004; 106. Shi Z, Xie H, Wang P, et al. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane 92. Rutala WA, Weber DJ; Healthcare Infection Control Practices Database Syst Rev 2013;8:CD008367.
Advisory Committee. Guideline for Disinfection and Steriliza- 107. Silvestri L, Weir I, Gregori D, et al. Effectiveness of oral chlor- tion in Healthcare Facilities, 2008. hexidine on nosocomial pneumonia, causative microorganisms Accessed April 1, and mortality in critically ill patients: a systematic review and meta-analysis. Minerva Anestesiol. Electronically published No- 93. Krueger WA, Lenhart FP, Neeser G, et al. Influence of combined vember 21, 2013.
intravenous and topical antibiotic prophylaxis on the incidence 108. Klompas M, Speck K, Howell MD, Greene LR, Berenholtz SM.
of infections, organ dysfunctions, and mortality in critically ill Reappraisal of routine oral care with chlorhexidine gluconate surgical patients: a prospective, stratified, randomized, double- for patients receiving mechanical ventilation: systematic review blind, placebo-controlled clinical trial. Am J Respir Crit Care and meta-analysis. JAMA Intern Med 2014;174(5):751–761.
109. DeRiso AJ 2nd, Ladowski JS, Dillon TA, Justice JW, Peterson 94. de Jonge E, Schultz MJ, Spanjaard L, et al. Effects of selective AC. Chlorhexidine gluconate 0.12% oral rinse reduces the in- decontamination of digestive tract on mortality and acquisition cidence of total nosocomial respiratory infection and nonpro- of resistant bacteria in intensive care: a randomised controlled phylactic systemic antibiotic use in patients undergoing heart 95. de Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination 110. Segers P, Speekenbrink RG, Ubbink DT, van Ogtrop ML, de of the digestive tract and oropharynx in ICU patients. N Engl Mol BA. Prevention of nosocomial infection in cardiac surgery J Med 2009;360(1):20–31.
by decontamination of the nasopharynx and oropharynx with 96. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E.
chlorhexidine gluconate: a randomized controlled trial. JAMA Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Da- 111. Siempos II, Ntaidou TK, Falagas ME. Impact of the admin- tabase Syst Rev 2009(4):CD000022.
istration of probiotics on the incidence of ventilator-associated This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update pneumonia: a meta-analysis of randomized controlled trials.
cheal tubes and incidence of ventilator-associated pneumonia: Crit Care Med 2010;38(3):954–962.
the NASCENT randomized trial. JAMA 2008;300(7):805–813.
112. Liu KX, Zhu YG, Zhang J, et al. Probiotics' effects on the 128. Delaney A, Gray H, Laupland KB, Zuege DJ. Kinetic bed ther- incidence of nosocomial pneumonia in critically ill patients: a apy to prevent nosocomial pneumonia in mechanically ven- systematic review and meta-analysis. Crit Care 2012;16(3): tilated patients: a systematic review and meta-analysis. Crit Care 113. Petrof EO, Dhaliwal R, Manzanares W, Johnstone J, Cook D, 129. Sud S, Sud M, Friedrich JO, Adhikari NK. Effect of mechanical Heyland DK. Probiotics in the critically ill: a systematic review ventilation in the prone position on clinical outcomes in pa- of the randomized trial evidence. Crit Care Med 2012;40(12): tients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. Can Med Assoc J 2008;178(9):1153– 114. Barraud D, Bollaert PE, Gibot S. Impact of the administration of probiotics on mortality in critically ill adult patients: a meta- 130. Alsaghir AH, Martin CM. Effect of prone positioning in pa- analysis of randomized controlled trials. Chest 2013;143(3): tients with acute respiratory distress syndrome: a meta-analysis.
Crit Care Med 2008;36(2):603–609.
115. Lherm T, Monet C, Nougiere B, et al. Seven cases of fungemia 131. Abroug F, Ouanes-Besbes L, Elatrous S, Brochard L. The effect with Saccharomyces boulardii in critically ill patients. Intensive of prone positioning in acute respiratory distress syndrome or Care Med 2002;28(6):797–801.
acute lung injury: a meta-analysis. Areas of uncertainty and 116. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces recommendations for research. Intensive Care Med 2008;34(6): cerevisiae fungemia: an emerging infectious disease. Clin Infect 132. Kopterides P, Siempos, II, Armaganidis A. Prone positioning 117. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus in hypoxemic respiratory failure: meta-analysis of randomized bacteremia, clinical significance, and patient outcome, with controlled trials. J Crit Care 2009;24(1):89–100.
special focus on probiotic L. rhamnosus GG. Clin Infect Dis 133. Abroug F, Ouanes-Besbes L, Dachraoui F, Ouanes I, Brochard L. An updated study-level meta-analysis of randomised con- 118. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomy- trolled trials on proning in ARDS and acute lung injury. Crit ces cerevisiae subtype boulardii fungemia in patients neighbor- ing those treated with a probiotic preparation of the organism.
134. Guerin C, Reignier J, Richard JC, et al. Prone positioning in J Clin Microbiol 2003;41(11):5340–5343.
severe acute respiratory distress syndrome. N Engl J Med 2013; 119. Graf C, Gavazzi G. Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces 135. Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer boulardii preparation. J Infect 2007;54(3):310–311.
prophylaxis in the new millennium: a systematic review and 120. Lorente L, Lecuona M, Jimenez A, Mora ML, Sierra A. Influ- meta-analysis. Crit Care Med 2010;38(11):2222–2228.
ence of an endotracheal tube with polyurethane cuff and sub- 136. Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ.
glottic secretion drainage on pneumonia. Am J Respir Crit Care Proton pump inhibitors versus histamine 2 receptor antago- nists for stress ulcer prophylaxis in critically ill patients: a sys- 121. Poelaert J, Depuydt P, De Wolf A, Van de Velde S, Herck I, tematic review and meta-analysis. Crit Care Med 2013;41(3): Blot S. Polyurethane cuffed endotracheal tubes to prevent early postoperative pneumonia after cardiac surgery: a pilot study.
137. Wang F, Wu Y, Bo L, et al. The timing of tracheotomy in J Thorac Cardiovasc Surg 2008;135(4):771–776.
critically ill patients undergoing mechanical ventilation: a sys- 122. Valencia M, Ferrer M, Farre R, et al. Automatic control of tematic review and meta-analysis of randomized controlled tracheal tube cuff pressure in ventilated patients in semi- recumbent position: a randomized trial. Crit Care Med 2007; 138. Reignier J, Mercier E, Le Gouge A, et al. Effect of not moni- toring residual gastric volume on risk of ventilator-associated 123. Nseir S, Zerimech F, Fournier C, et al. Continuous control of pneumonia in adults receiving mechanical ventilation and early tracheal cuff pressure and microaspiration of gastric contents enteral feeding: a randomized controlled trial. JAMA 2013; in critically ill patients. Am J Respir Crit Care Med 2011;184(9): 139. Casaer MP, Mesotten D, Hermans G, et al. Early versus late 124. Caruso P, Denari S, Ruiz SA, Demarzo SE, Deheinzelin D.
parenteral nutrition in critically ill adults. N Engl J Med 2011; Saline instillation before tracheal suctioning decreases the in- cidence of ventilator-associated pneumonia. Crit Care Med 140. Vonberg RP, Eckmanns T, Welte T, Gastmeier P. Impact of the suctioning system (open vs. closed) on the incidence of ven- 125. Yao LY, Chang CK, Maa SH, Wang C, Chen CC. Brushing teeth tilation-associated pneumonia: meta-analysis of randomized with purified water to reduce ventilator-associated pneumonia.
controlled trials. Intensive Care Med 2006;32(9):1329–1335.
J Nurs Res 2011;19(4):289–297.
141. Jongerden IP, Rovers MM, Grypdonck MH, Bonten MJ. Open 126. Alhazzani W, Smith O, Muscedere J, Medd J, Cook D. Tooth- and closed endotracheal suction systems in mechanically ven- brushing for critically ill mechanically ventilated patients: a tilated intensive care patients: a meta-analysis. Crit Care Med systematic review and meta-analysis of randomized trials eval- uating ventilator-associated pneumonia. Crit Care Med 2013; 142. Siempos II, Vardakas KZ, Falagas ME. Closed tracheal suction systems for prevention of ventilator-associated pneumonia. Br 127. Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotra- J Anaesth 2008;100(3):299–306.
This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 143. Jongerden IP, Buiting AG, Leverstein–van Hall MA, et al. Effect very low birth weight infants. Pediatrics 2006;117(2):e137– of open and closed endotracheal suctioning on cross-trans- mission with gram-negative bacteria: a prospective crossover 160. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Pro- study. Crit Care Med 2011;39(6):1313–1321.
longed initial empirical antibiotic treatment is associated with 144. Lorente L, Lecuona M, Jimenez A, Mora ML, Sierra A. Tracheal adverse outcomes in premature infants. J Pediatr 2011;159(5): suction by closed system without daily change versus open system. Intensive Care Med 2006;32(4):538–544.
161. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure 145. Maggiore SM. Endotracheal suctioning, ventilator-associated in the newborn intensive care unit and the risk of necrotizing pneumonia, and costs: open or closed issue? Intensive Care enterocolitis. J Pediatr 2011;159(3):392–397.
162. Shah P, Nathan E, Doherty D, Patole S. Prolonged exposure 146. Dudeck MA, Horan T, Peterson KD, et al. National Healthcare to antibiotics and its associations in extremely preterm neo- Safety Network (NHSN) Report, Data Summary for 2011, Device- nates—the western Australian experience. J Matern Fetal Neo- Associated Module. Atlanta: Centers for Disease Control and Pre- natal Med 2013;26(17):1710–1714.
163. Weintraub AS, Ferrara L, Deluca L, et al. Antenatal antibiotic Accessed April 1, 2014.
exposure in preterm infants with necrotizing enterocolitis. J 147. Bhandari V, Finer NN, Ehrenkranz RA, et al. Synchronized nasal intermittent positive-pressure ventilation and neonatal 164. Davis PG, Henderson-Smart DJ. Extubation from low-rate in- termittent positive airways pressure versus extubation after a 148. Finer NN, Carlo WA, Walsh MC, et al. Early CPAP versus trial of endotracheal continuous positive airways pressure in surfactant in extremely preterm infants. N Engl J Med 2010; intubated preterm infants. Cochrane Database Syst Rev 2001(4): 149. Bhandari V. Nasal intermittent positive pressure ventilation in 165. Kaczmarek J, Kamlin CO, Morley CJ, Davis PG, Sant'anna GM.
the newborn: review of literature and evidence-based guide- Variability of respiratory parameters and extubation readiness lines. J Perinatol 2010;30(8):505–512.
in ventilated neonates. Arch Dis Child Fetal Neonatal Ed 2013; 150. Hamid MH, Malik MA, Masood J, Zia A, Ahmad TM. Ven- tilator-associated pneumonia in children. J Coll Physicians Surg 166. Kamlin CO, Davis PG, Argus B, Mills B, Morley CJ. A trial of spontaneous breathing to determine the readiness for extu- 151. Ng E, Taddio A, Ohlsson A. Intravenous midazolam infusion bation in very low birth weight infants: a prospective evalua- for sedation of infants in the neonatal intensive care unit. Coch- tion. Arch Dis Child Fetal Neonatal Ed 2008;93(4):F305–F306.
rane Database Syst Rev 2012;6:CD002052.
167. Rojas MA, Lozano JM, Rojas MX, et al. Prophylactic probiotics 152. Veldman A, Trautschold T, Weiss K, Fischer D, Bauer K. Char- to prevent death and nosocomial infection in preterm infants.
acteristics and outcome of unplanned extubation in ventilated 168. Manzoni P, Mostert M, Leonessa ML, et al. Oral supplemen- preterm and term newborns on a neonatal intensive care unit.
tation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: 153. Samransamruajkit R, Jirapaiboonsuk S, Siritantiwat S, et al.
a randomized study. Clin Infect Dis 2006;42(12):1735–1742.
Effect of frequency of ventilator circuit changes (3 vs 7 days) 169. De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR.
on the rate of ventilator-associated pneumonia in PICU. J Crit Lactobacillus rhamnosus GG bacteremia associated with pro- biotic use in a child with short gut syndrome. Pediatr Infect 154. Hsieh TC, Hsia SH, Wu CT, Lin TY, Chang CC, Wong KS.
Dis J 2005;24(3):278–280.
Frequency of ventilator-associated pneumonia with 3-day ver- 170. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus sus 7-day ventilator circuit changes. Pediatr Neonatol 2010; bacteremia during probiotic treatment of short gut syndrome.
J Pediatr Gastroenterol Nutr 2004;38(4):457–458.
155. Aly H, Badawy M, El-Kholy A, Nabil R, Mohamed A. Ran- 171. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota domized, controlled trial on tracheal colonization of ventilated J, Shetty AK. Lactobacillus sepsis associated with probiotic ther- infants: can gravity prevent ventilator-associated pneumonia? 172. Foglia E, Meier MD, Elward A. Ventilator-associated pneu- 156. Taylor JE, Hawley G, Flenady V, Woodgate PG. Tracheal suc- monia in neonatal and pediatric intensive care unit patients.
tioning without disconnection in intubated ventilated neo- Clin Microbiol Rev 2007;20(3):409–425.
nates. Cochrane Database Syst Rev 2011(12):CD003065.
173. Bigham MT, Amato R, Bondurrant P, et al. Ventilator-associ- 157. van Veenendaal MB, Miedema M, de Jongh FH, van der Lee ated pneumonia in the pediatric intensive care unit: charac- JH, Frerichs I, van Kaam AH. Effect of closed endotracheal terizing the problem and implementing a sustainable solution.
suction in high-frequency ventilated premature infants mea- J Pediatr 2009;154(4):582e2–587e2.
sured with electrical impedance tomography. Intensive Care 174. Taira BR, Fenton KE, Lee TK, et al. Ventilator-associated pneu- monia in pediatric trauma patients. Pediatr Crit Care Med 2009; 158. Terrin G, Passariello A, De Curtis M, et al. Ranitidine is as- sociated with infections, necrotizing enterocolitis, and fatal out- 175. Gautam A, Ganu SS, Tegg OJ, Andresen DN, Wilkins BH, Schell come in newborns. Pediatrics 2012;129(1):e40–e45.
DN. Ventilator-associated pneumonia in a tertiary paediatric 159. Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker intensive care unit: a 1-year prospective observational study.
therapy and higher incidence of necrotizing enterocolitis in Crit Care Resusc 2012;14(4):283–289.
This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM strategies to prevent vap: 2014 update 176. Awasthi S, Tahazzul M, Ambast A, Govil YC, Jain A. Longer in ventilated children. Pediatr Crit Care Med 2012;13(2):131– duration of mechanical ventilation was found to be associated with ventilator-associated pneumonia in children aged 1 month 193. Sebastian MR, Lodha R, Kapil A, Kabra SK. Oral mucosal to 12 years in India. J Clin Epidemiol 2013;66(1):62–66.
decontamination with chlorhexidine for the prevention of ven- 177. Liljemark WF, Bloomquist C. Human oral microbial ecology tilator-associated pneumonia in children—a randomized, con- and dental caries and periodontal diseases. Crit Rev Oral Biol trolled trial. Pediatr Crit Care Med 2012;13(5):e305–e310.
194. Wan AK, Seow WK, Purdie DM, Bird PS, Walsh LJ, Tudehope 178. Kononen E. Development of oral bacterial flora in young chil- DI. The effects of chlorhexidine gel on Streptococcus mutans dren. Ann Med 2000;32(2):107–112.
infection in 10-month-old infants: a longitudinal, placebo-con- 179. Javouhey E, Barats A, Richard N, Stamm D, Floret D. Non- trolled, double-blind trial. Pediatr Dent 2003;25(3):215–222.
invasive ventilation as primary ventilatory support for infants 195. Jacomo AD, Carmona F, Matsuno AK, Manso PH, Carlotti AP.
with severe bronchiolitis. Intensive Care Med 2008;34(9):1608– Effect of oral hygiene with 0.12% chlorhexidine gluconate on the incidence of nosocomial pneumonia in children under- 180. Yanez LJ, Yunge M, Emilfork M, et al. A prospective, random- going cardiac surgery. Infect Control Hosp Epidemiol 2011;32(6): ized, controlled trial of noninvasive ventilation in pediatric acute respiratory failure. Pediatr Crit Care Med 2008;9(5):484– 196. Kusahara DM, Friedlander LT, Peterlini MA, Pedreira ML. Oral care and oropharyngeal and tracheal colonization by gram- 181. Ferguson LP, Walsh BK, Munhall D, Arnold JH. A spontaneous negative pathogens in children. Nurs Crit Care 2012;17(3):115– breathing trial with pressure support overestimates readiness for extubation in children. Pediatr Crit Care Med 2011;12(6): 197. Kusahara DM, Peterlini MA, Pedreira ML. Oral care with 0.12% chlorhexidine for the prevention of ventilator-associated 182. Randolph AG, Wypij D, Venkataraman ST, et al. Effect of me- pneumonia in critically ill children: randomised, controlled and chanical ventilator weaning protocols on respiratory outcomes double blind trial. Int J Nurs Stud 2012;49(11):1354–1363.
in infants and children: a randomized controlled trial. JAMA 198. Pedreira ML, Kusahara DM, de Carvalho WB, Nunez SC, Peterlini MA. Oral care interventions and oropharyngeal col- 183. Foronda FK, Troster EJ, Farias JA, et al. The impact of daily onization in children receiving mechanical ventilation. Am J evaluation and spontaneous breathing test on the duration of Crit Care 2009;18(4):319–328.
pediatric mechanical ventilation: a randomized controlled trial.
199. Yildizdas D, Yapicioglu H, Yilmaz HL. Occurrence of venti- Crit Care Med 2011;39(11):2526–2533.
lator-associated pneumonia in mechanically ventilated pedi- 184. Newth CJ, Venkataraman S, Willson DF, et al. Weaning and atric intensive care patients during stress ulcer prophylaxis with extubation readiness in pediatric patients. Pediatr Crit Care sucralfate, ranitidine, and omeprazole. J Crit Care 2002;17(4): 185. Lucas da Silva PS, de Carvalho WB. Unplanned extubation in 200. Lopriore E, Markhorst DG, Gemke RJ. Ventilator-associated pediatric critically ill patients: a systematic review and best pneumonia and upper airway colonisation with gram negative practice recommendations. Pediatr Crit Care Med 2010;11(2): bacilli: the role of stress ulcer prophylaxis in children. Intensive Care Med 2002;28(6):763–767.
186. Curley MA, Schwalenstocker E, Deshpande JK, et al. Tailoring 201. Morrow BM, Mowzer R, Pitcher R, Argent AC. Investigation the Institute for Health Care Improvement 100,000 Lives Cam- into the effect of closed-system suctioning on the frequency of paign to pediatric settings: the example of ventilator-associated pediatric ventilator-associated pneumonia in a developing pneumonia. Pediatr Clin North Am 2006;53(6):1231–1251.
country. Pediatr Crit Care Med 2012;13(1):e25–e32.
187. American Dental Association. Your child's growing smile. J Am 202. Hatler CW, Mast D, Corderella J, et al. Using evidence and Dent Assoc 2012;143(1):88.
process improvement strategies to enhance healthcare out- 188. Tsai HH, Lin FC, Chang SC. Intermittent suction of oral se- cretions before each positional change may reduce ventilator- comes for the critically ill: a pilot project. Am J Crit Care 2006; associated pneumonia: a pilot study. Am J Med Sci 2008;336(5): 203. Pronovost PJ, Berenholtz SM, Needham DM. Translating evi- 189. Gopalareddy V, He Z, Soundar S, et al. Assessment of the dence into practice: a model for large scale knowledge trans- prevalence of microaspiration by gastric pepsin in the airway lation. BMJ 2008;337:a1714.
of ventilated children. Acta Paediatr 2008;97(1):55–60.
204. Krimsky WS, Mroz IB, McIlwaine JK, et al. A model for in- 190. Weiss M, Dullenkopf A, Fischer JE, Keller C, Gerber AC. Pro- creasing patient safety in the intensive care unit: increasing the spective randomized controlled multi-centre trial of cuffed or implementation rates of proven safety measures. Qual Saf uncuffed endotracheal tubes in small children. Br J Anaesth Health Care 2009;18(1):74–80.
205. Hawe CS, Ellis KS, Cairns CJ, Longmate A. Reduction of ven- 191. Kleinman ME, de Caen AR, Chameides L, et al. Part 10: pe- tilator-associated pneumonia: active versus passive guideline diatric basic and advanced life support: 2010 International implementation. Intensive Care Med 2009;35(7):1180–1186.
Consensus on Cardiopulmonary Resuscitation and Emergency 206. Rello J, Lode H, Cornaglia G, Masterton R. A European care Cardiovascular Care Science with Treatment Recommenda- bundle for prevention of ventilator-associated pneumonia. In- tions. Circulation 2010;122(16 suppl 2):S466–S515.
tensive Care Med 2010;36(5):773–780.
192. Gupta K, Gupta VK, Jayashree M, Singhi S. Randomized con- 207. Berenholtz SM, Pham JC, Thompson DA, et al. Collaborative trolled trial of interrupted versus continuous sedative infusions cohort study of an intervention to reduce ventilator-associated This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM infection control and hospital epidemiology august 2014, vol. 35, no. 8 pneumonia in the intensive care unit. Infect Control Hosp Ep- plementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine 208. Klompas M. Ventilator-associated pneumonia: is zero possible? Through Pathway Assessment of Critical Therapy in Hospital- Clin Infect Dis 2010;51(10):1123–1126.
Acquired Pneumonia (IMPACT-HAP) study. Crit Care 2011; 209. Crunden E, Boyce C, Woodman H, Bray B. An evaluation of the impact of the ventilator care bundle. Nurs Crit Care 2005; 226. Scales DC, Dainty K, Hales B, et al. A multifaceted intervention for quality improvement in a network of intensive care units: 210. Burger CD, Resar RK. "Ventilator bundle" approach to pre- a cluster randomized trial. JAMA 2011;305(4):363–372.
vention of ventilator-associated pneumonia. Mayo Clin Proc 227. Rello J, Afonso E, Lisboa T, et al. A care bundle approach for prevention of ventilator-associated pneumonia. Clin Microbiol 211. Apisarnthanarak A, Pinitchai U, Thongphubeth K, et al. Ef- fectiveness of an educational program to reduce ventilator- 228. Grimshaw J, Eccles M, Thomas R, et al. Toward evidence-based associated pneumonia in a tertiary care center in Thailand: a quality improvement: evidence (and its limitations) of the ef- 4-year study. Clin Infect Dis 2007;45(6):704–711.
fectiveness of guideline dissemination and implementation 212. Youngquist P, Carroll M, Farber M, et al. Implementing a ven- strategies 1966–1998. J Gen Intern Med 2006;21(suppl 2):S14– tilator bundle in a community hospital. Jt Comm J Qual Patient 229. Berenholtz S, Pronovost PJ. Barriers to translating evidence 213. Bloos F, Muller S, Harz A, et al. Effects of staff training on the into practice. Curr Opin Crit Care 2003;9(4):321–325.
care of mechanically ventilated patients: a prospective cohort 230. Bouadma L, Mourvillier B, Deiler V, et al. Changes in knowl- study. Br J Anaesth 2009;103(2):232–237.
edge, beliefs, and perceptions throughout a multifaceted be- 214. Sinuff T, Muscedere J, Cook DJ, et al. Implementation of clinical havioral program aimed at preventing ventilator-associated practice guidelines for ventilator-associated pneumonia: a mul- pneumonia. Intensive Care Med 2010;36(8):1341–1347.
ticenter prospective study. Crit Care Med 2013;41(1):15–23.
231. Bassi GL, Ferrer M, Saucedo LM, Torres A. Do guidelines 215. Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, change outcomes in ventilator-associated pneumonia? Curr Nolan T. Using a bundle approach to improve ventilator care Opin Infect Dis 2010;23(2):171–177.
processes and reduce ventilator-associated pneumonia. Jt 232. Lyerla F. Design and implementation of a nursing clinical de- Comm J Qual Patient Saf 2005;31(5):243–248.
cision support system to promote guideline adherence. Comput 216. Ellingson K, Haas JP, Aiello AE, et al. Strategies to prevent Inform Nurs 2008;26(4):227–233.
healthcare-associated infections through hand hygiene. Infect 233. Sinuff T, Muscedere J, Cook D, Dodek P, Heyland D. Venti- Control Hosp Epidemiol 35(8):937–960 (in this issue).
lator-associated pneumonia: improving outcomes through 217. Boles JM, Bion J, Connors A, et al. Weaning from mechanical guideline implementation. J Crit Care 2008;23(1):118–125.
ventilation. Eur Respir J 2007;29(5):1033–1056.
234. Omrane R, Eid J, Perreault MM, et al. Impact of a protocol 218. Aragon D, Sole ML. Implementing best practice strategies to for prevention of ventilator-associated pneumonia. Ann Phar- prevent infection in the ICU. Crit Care Nurs Clin North Am 235. Zaydfudim V, Dossett LA, Starmer JM, et al. Implementation 219. Burns SM, Earven S, Fisher C, et al. Implementation of an of a real-time compliance dashboard to help reduce SICU ven- institutional program to improve clinical and financial out- tilator-associated pneumonia with the ventilator bundle. Arch comes of mechanically ventilated patients: one-year outcomes and lessons learned. Crit Care Med 2003;31(12):2752–2763.
236. Salahuddin N, Zafar A, Sukhyani L, et al. Reducing ventilator- 220. Brierley J, Highe L, Hines S, Dixon G. Reducing VAP by in- associated pneumonia rates through a staff education pro- stituting a care bundle using improvement methodology in a gramme. J Hosp Infect 2004;57(3):223–227.
UK paediatric intensive care unit. Eur J Pediatr 2012;171(2): 237. Westwell S. Implementing a ventilator care bundle in an adult intensive care unit. Nurs Crit Care 2008;13(4):203–207.
221. Weireter LJ Jr, Collins JN, Britt RC, Reed SF, Novosel TJ, Britt 238. Pinto A, Burnett S, Benn J, et al. Improving reliability of clinical LD. Impact of a monitored program of care on incidence of care practices for ventilated patients in the context of a patient ventilator-associated pneumonia: results of a longterm perfor- safety improvement initiative. J Eval Clin Pract 2011;17(1):180– mance-improvement project. J Am Coll Surg 2009;208(5):700– 239. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging 222. Johnson V, Mangram A, Mitchell C, Lorenzo M, Howard D, consensus on rating quality of evidence and strength of rec- Dunn E. Is there a benefit to multidisciplinary rounds in an open trauma intensive care unit regarding ventilator-associated 240. GRADE. Canadian Task Force on Preventive Health Care web- pneumonia? Am Surg 2009;75(12):1171–1174.
site. Accessed De- 223. Heimes J, Braxton C, Nazir N, et al. Implementation and en- cember 31, 2013.
forcement of ventilator-associated pneumonia prevention 241. Rosenthal VD, Rodriguez-Calderon ME, Rodriguez-Ferrer M, strategies in trauma patients. Surg Infect (Larchmt) 2011;12(2): et al. Findings of the International Nosocomial Infection Con- trol Consortium (INICC), part II: impact of a multidimen- 224. Craven DE. Preventing ventilator-associated pneumonia in sional strategy to reduce ventilator-associated pneumonia in adults: sowing seeds of change. Chest 2006;130(1):251–260.
neonatal intensive care units in 10 developing countries. Infect 225. Mangino JE, Peyrani P, Ford KD, et al. Development and im- Control Hosp Epidemiol 2012;33(7):704–710.
This content downloaded from on Mon, 21 Jul 2014 17:07:44 PM


CliniCal Guidelines Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline Authors: Richard s. legro, silva a. arslanian, david a. ehrmann, Kathleen M. Hoeger, M. Hassan Murad, Renato Pasquali, and Corrine K. Welt Affiliations: The Penn state university College of Medicine (R.s.l.), Hershey, Pennsylvania 17033; Children's Hospital of Pittsburgh (s.a.a.), university of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15224; university of Chicago (d.a.e.), Chicago, illinois 60637; university of Rochester Medical Center (K.M.H.), Rochester, new York 14627; Mayo Clinic (M.H.M.), Rochester, Minnesota 55905; Orsola-Malpighi Hospital, university alma Mater studiorum, (R.P.), 40126 Bologna, italy; and Massachusetts General Hospital (C.K.W.), Boston, Massachusetts 02114

The antimalarial and people suffering from the disease per year. Africa accounts forover 90% of reported cases, with an annual 20% increase of cytotoxic drug cryptolepine malaria-related illness and death. Malaria is responsible for as many deaths per annum as AIDS for all of the last 15 years. Drug intercalates into DNA at resistance to malaria has become one of the most significantthreats to human health and the search for new effective drugs is